...
首页> 外文期刊>Journal of interferon and cytokine research: The official journal of the International Society for Interferon and Cytokine Research >Differential effects of IFN-beta1b on the proliferation of human vascular smooth muscle and endothelial cells.
【24h】

Differential effects of IFN-beta1b on the proliferation of human vascular smooth muscle and endothelial cells.

机译:IFN-beta1b对人血管平滑肌和内皮细胞增殖的不同作用。

获取原文
获取原文并翻译 | 示例

摘要

The effect of human interferon (IFN)-beta1b (Betaseron) on the proliferation of cultured human vascular smooth muscle and endothelial cells was tested in vitro. IFN-beta1b inhibited thymidine incorporation and growth of primary cultures of human aortic and coronary artery smooth muscle in a concentration-dependent manner. The same concentrations of IFN-beta1b did not inhibit thymidine incorporation or growth of primary cultures of human aortic or coronary artery endothelial cells. IFN-beta1b induced the expression of MxA (an antiviral protein induced by type I IFNs) in both smooth muscle and endothelial cells, suggesting that both cell types express receptors for type I IFNs. The growth-inhibitory effect of IFN-beta1b could be mimicked by commercially available human IFN-beta, but not by IFN-alpha2 or IFN-alpha8. The effect of IFN-beta1b was species specific, as it did not inhibit thymidine incorporation in aortic smooth muscle cells derived from pig, rabbit, rat, or mouse. The action of IFN-beta1b on smooth muscle cells persisted for at least 4 days following a 24 h preincubation with IFN-beta1b. Human vascular smooth muscle cells treated with IFN-beta1b did not release lactate dehydrogenase, nor did they show any morphologic change, suggesting that IFN-beta1b was not toxic to the human vascular smooth muscle cells. IFN-beta1b inhibited vascular smooth muscle growth while having no growth-inhibitory effect on endothelial cells obtained from the same blood vessel, making it a potential candidate for treating pathologic conditions where abnormal vascular smooth muscle proliferation is implicated, such as restenosis following balloon angioplasty or smooth muscle proliferation following vascular stenting.
机译:在体外测试了人干扰素(IFN)-beta1b(贝他塞隆)对培养的人血管平滑肌和内皮细胞增殖的影响。 IFN-beta1b以浓度依赖的方式抑制人主动脉和冠状动脉平滑肌原代培养物中胸苷的掺入和生长。相同浓度的IFN-beta1b不会抑制胸腺嘧啶核苷的掺入或人主动脉或冠状动脉内皮细胞原代培养物的生长。 IFN-beta1b诱导平滑肌和内皮细胞中MxA(一种由I型IFN诱导的抗病毒蛋白)的表达,表明这两种细胞类型均表达I型IFN的受体。 IFN-beta1b的生长抑制作用可以通过市售的人IFN-beta来模仿,但不能通过IFN-alpha2或IFN-alpha8来模仿。 IFN-beta1b的作用具有物种特异性,因为它不会抑制胸腺嘧啶核苷掺入源自猪,兔,大鼠或小鼠的主动脉平滑肌细胞中。与IFN-beta1b预温育24小时后,IFN-beta1b对平滑肌细胞的作用持续至少4天。用IFN-β1b处理的人血管平滑肌细胞未释放乳酸脱氢酶,也未显示任何形态变化,表明IFN-β1b对人血管平滑肌细胞无毒。 IFN-beta1b抑制血管平滑肌生长,同时对从同一血管获得的内皮细胞没有生长抑制作用,使其成为治疗涉及血管平滑肌异常增生的病理状况的潜在候选人,例如球囊血管成形术后的再狭窄或血管支架置入后平滑肌增生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号